<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219971</url>
  </required_header>
  <id_info>
    <org_study_id>HR-KB101</org_study_id>
    <secondary_id>ChiCTR-TRC-14005111</secondary_id>
    <nct_id>NCT02219971</nct_id>
  </id_info>
  <brief_title>Phase I Study of Kukoamine B Mesilate in Healthy Volunteers</brief_title>
  <official_title>Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance and Pharmacokinetics of a Single Intravenous Injection Kukoamine B Mesilate in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Chasesun Pharmaceutical Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southwest Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Chasesun Pharmaceutical Co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, tolerance and pharmacokinetics of a single
      intravenous injection Kukoamine B Mesilate in health volunteer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">May 6, 2015</completion_date>
  <primary_completion_date type="Actual">May 6, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events.</measure>
    <time_frame>7 days</time_frame>
    <description>AE,physical examination,monitoring of vital signs, Laboratory examination,ECG etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters (t1/2,AUC0-inf,AUClast and Cmax;Fe0-48h(%),CLr24h)</measure>
    <time_frame>48h</time_frame>
    <description>Blood:（Pre Test）0,20min,40min after initiation of drug administration and 0,10min,20min,30min,45min,1h,1.5h,2h,2.5h,3h,4h,6h,8h,12h,24h after the end of administration;(Formal Test) 0,20min,40min after initiation of drug administration and 0,30min,1h,2h,3h,4h,6h,8h,12h,16h,24h after the end of administration; Urine:(Pre Test) 0,0-4h,4-8h,8-12h,12-24h,24-48h after initiation of drug administration;(Formal Test) 0,0-5h,5-9h,9-13h,13-25h,25-49h after initiation of drug administration .</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.005mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.02mg/kg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.04mg/kg +Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.08mg/kg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.12mg/kg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.24mg/kg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kukoamine B Mesilate 0.48mg/kg + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kukoamine B Mesilate</intervention_name>
    <description>Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.</description>
    <arm_group_label>Kukoamine B Mesilate 0.005mg/kg</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.02mg/kg + Placebo</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.04mg/kg +Placebo</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.08mg/kg + Placebo</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.12mg/kg + Placebo</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.24mg/kg + Placebo</arm_group_label>
    <arm_group_label>Kukoamine B Mesilate 0.48mg/kg + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: male or female, each sex ratio does not exceed 2/3;

          -  18-45 years (including upper and lower limit), the general situation is good;

          -  Body mass index (BMI) in 19-28 (including upper and lower limit of the range), BW ≥
             50kg (female) and 60kg (male);

          -  Nearly half of the year, no child care program and agreed to take effective measures
             to contraception during the study period, women of childbearing age blood pregnancy
             test was negative;

          -  Subjects to fully understand the purpose, properties, method and reactions may occur
             of test drug trials.Voluntarily signed the informed consents, and agreed to abide by
             the requirements of clinical protocols.

        Exclusion Criteria:

          -  Primary disease in important organs;

          -  Mental or physical disability;

          -  Familial hereditary disease;

          -  Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood
             pressure greater than 90~140mmHg, beyond the scope of 50~90mmHg, Or pulse (HR) beyond
             50bpm~100bpm

          -  Abnormal results of any clinically meaningful physical examination, vital signs, ECG
             or clinical laboratory;

          -  History of immunodeficiency diseases, including HIV antibody positive;

          -  Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C
             / syphilis positive;

          -  Alcohol and drug abusers;

          -  Smoking and drinking are (drinking 14 units of alcohol per week: 1 unit = beer 285 ml,
             or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and
             drinking in the test period;

          -  Any discharge period may affect the study drug, or in the past 3 months participated
             in any drug clinical trials;

          -  Before entering the group 4 weeks using any prescription drugs before entering the
             group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics,
             food additives), or into the group within 2 weeks before taking effect of drug
             metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of
             acetaminophen, but must record report in CRF;

          -  The last 3 months had a history of blood donation or significant blood loss (more than
             400ml);

          -  There are drugs, the clinical significance of the history of food allergy and atopic
             allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs
             or similar drug allergy test;

          -  Lactating women, pregnant women or unable to take effective contraceptive measures;

          -  Researchers believe that the other is not suitable to take the test factors
             participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SHUAI CHEN</last_name>
    <role>Study Director</role>
    <affiliation>TIAN JIN CHASE SUN PHARMACEUTICAL CO.,LTD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

